Pasireotide pamoate, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
MedKoo Cat#: 329635
Name: Pasireotide pamoate
CAS#: 396091-79-5 (pamoate)
Chemical Formula: C81H82N10O15
Exact Mass:
Molecular Weight: 1435.60
Elemental Analysis: C, 67.77; H, 5.76; N, 9.76; O, 16.72
The following data is based on the product molecular weight 1,435.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
